+ Click for EPISODE TRANSCRIPT

---

DISCLAIMER: This text is the output of AI based transcribing from an audio recording. Although the transcription is largely accurate, in some cases it is incomplete or inaccurate due to inaudible passages or transcription errors and should not be treated as an authoritative record. Nothing that you read here constitutes advice medical or otherwise. Always consult with a healthcare professional before making changes to a healthcare plan.

Scott Benner 0:00
Hello friends, welcome to episode 1134 of the Juicebox Podcast.

On today's podcast Jake leeches back from Dexcom. He's going to talk about Dexcom G seven, you guys asked a bunch of questions I asked him of Jake, and he's here to tell us about a new product called the Dexcom stello. I said hello stello But he said that was not the marketing campaign. I thought it was amazing. Whatever. While you're listening, please remember that nothing you hear on the Juicebox Podcast should be considered advice, medical or otherwise, always consult a physician before making any changes to your health care plan, or becoming bold with insulin. When you place your first order for ag one with my link, you'll get five free travel packs and a free year supply of vitamin D. Drink ag one.com/juice box. Don't forget to save 40% off of your entire order at cozy earth.com All you have to do is use the offer code juice box at checkout. That's juice box at checkout to save 40% at cozy earth.com. If you're looking for community around type one diabetes, check out the Juicebox Podcast private Facebook group Juicebox Podcast type one diabetes, but everybody is welcome type one type two gestational loved ones. It doesn't matter to me. US med is sponsoring this episode of The Juicebox Podcast and we've been getting our diabetes supplies from us med for years. You can as well us med.com/juice box or call 888721151 for use the link or the number get your free benefits check it get started today with us med today's episode of The Juicebox Podcast is sponsored by the contour next gen blood glucose meter. This is the meter that my daughter has on her person right now. It is incredibly accurate and waiting for you at contour next one.com/juicebox. And no Dexcom is not sponsoring this episode. You can use my link in the show notes to find out more about Dexcom what no Hell, alarms are going off. Everybody run dexcom.com forward slash juicebox. The alarm was just to remind me to make a phone call. Jake, I appreciate you coming on. I know we're short on time. I have a lot of questions here. Do you mind if I jump right in?

Jake Leach 2:36
Let's do it, Scott.

Scott Benner 2:37
Okay. Is it pronounced stello? Like hello?

Jake Leach 2:40
It is Hello. You got it.

Scott Benner 2:42
Okay, is it just for type twos? Can people with pre diabetes get it? What about other biohacking stuff? Like where's it going to fall in the market? Yeah, so

Jake Leach 2:51
we're super excited about the stellar product. It's specifically designed for people with type two diabetes that are not taking insulin. And there's some very specific reasons for that. It's really around the product features and the needs that it's trying to address for users. We can go into those. But you know, it's there's that 25 million people out there in the US that have type two that do not treat their diabetes with insulin. And so it's really targeted. There's not great availability of CGM for that population. And so that's really what we're going after it's specifically designed for their needs, is built on the same performance and accuracy reliability of Dexcom CGM, but has a new mobile app that is completely redesigned for that user group.

Scott Benner 3:37
Why do people in this category need something different than what you already make? why did why? What was the necessity for a different product? Yeah, so

Jake Leach 3:45
there's a couple of ways to look at but one of the most important ones is that this is this population is not at risk of hypoglycemia. There's, you know, the really important components of our G seven product, and G six and previous generations of that G series that has the predictive low glucose alerts, the low glucose alerts, the urgent low, the 55, all of that technology was developed about keeping people safe from hypoglycemia. This group of people with type two that aren't using insulin, and also don't have a risk of hypoglycemia. That's what this product is designed for. So it doesn't have those alerts. The way we think about it is it has all the information and insights without the interruptions of alerts, they don't need those. And so it's a much simpler product. When I know someone who is using G seven and isn't taking insulin, it doesn't have hyperglycemia challenges. I basically say turn off all those alerts, get all the turmoil in your urgent low, you can't turn off but all the rest of them, you can just turn them off because you don't want you don't want those, you know, nuisance alarms happening.

Scott Benner 4:49
So if there's a person who's typed to right now wearing g7, for example, and they do get low, for whatever reason, maybe they're I don't know, who cares. Why will they be forced To be to go on to stello buy insurance needs, now they'll be able to stay with what they have.

Jake Leach 5:05
Yeah, if you're if you're covered, if you're, you know, g7, if you have coverage for g7, that's not going to change. Coverage for g7 is really strong across all multiple daily injections, insulin pump therapies, Basal insulin, and then there is some coverage. For people who are in this category that, you know, they don't have hypoglycemic challenges. They're not an insulin, but they're using CGM. And so we actually did a published a study of 7200 of our users that went on to G six, and used it to really increase the GERD increase their time and range, but they were all people with type two diabetes, that were not treating it with insulin, they happen to be able to get access to the device, and so they're using it. And so but you know, they're basically using g7. They've got the real time data, but stello is going to be a much better product for that group.

Scott Benner 5:54
So is there a accuracy difference between stello and G seven? No, it's

Jake Leach 5:59
exactly the same level of performance, accuracy, reliability, it is the first 15 Day sensor, okay, that we're launching. And so it has 15 day where it's on the g7 platform in terms of hardware, but it's branded different, and it has a completely different mobile app, the way we think about it is accuracy is extremely important to anyone who's monetary glucose, whether they're, you know, they're treating their diabetes with insulin. Maybe they're not. Or even you know, when you think about health and wellness, it's so important for CGM to be accurate, you can easily be misled to think you have a metabolic disorder if the CGM is off by even a little bit. Sure.

Scott Benner 6:38
So does this mean we're going to get a 15 day where G seven,

Jake Leach 6:41
that's the goal? Yeah, we're working on a 15 day where G seven as well, we're actually doing clinical trials right now, on some enhanced technology on the sensor probe, in particular, to ensure we get the low level of reliability, we want out to 15 days, we have a very high bar for performance and reliability out to the total sensor wear time. And so we take that very seriously, because we know that our customer satisfaction has a lot to do with the performance and reliability of our sensors. And knowing that we want to make sure that the duration is truly the full 15 days and not something, you know, less than that plus

Scott Benner 7:23
what you just talked about, about being safe in lower numbers and and having that accuracy down there is really important. All right, well, they need a prescription. It sounds like yes,

Jake Leach 7:32
yeah, right now, you know all CGM is in the United States, FDA has declared their prescription devices. And so the idea is, you know, you need the performance need accurate accuracy, reliability, but the other their prescription devices until the FDA decides they're not

Scott Benner 7:48
the is the biohacking market big enough for you guys to be interested in? And does this product put you closer to that

Jake Leach 7:55
ease? Great question I do that we've definitely feel that there is, you know, a really large opportunity outside of diabetes for CGM and metabolic health, and generally healthy living thing about pre diabetes. The stello product is specifically designed for this group of type two users that don't have great access to CGM, and we really want to build a product for them. And you know, it's a large group of people that could significantly benefit from having real time CGM data. And so that's what we're focused on. Yeah, it puts us closer towards towards the group. And you know, as we go down that acuity curve, but we felt like, this is a group that doesn't have a product designed for them today. And that's why we basically focused on on that, oh, my

Scott Benner 8:38
brother, I'm gonna call him as soon as this is over, I've been able to give him a sensor once in a while. And the difference it makes in his life with type two is insane. And but his insurance won't help him get a CGM at this moment, with type two because he doesn't use insulin. Our

Jake Leach 8:54
goal is to basically generate whatever evidence is required so that we can ultimately get coverage for this population. Because there you're right, the benefits are so clear, yeah, many folks, you know, that aren't taking insulin are, you know, haven't ever really monitored their blood glucose. And so they have no idea how it changes throughout the day I was talking to someone recently, who had started using CGM is in this category has type two recently diagnosed type two, and didn't really, you know, just was told over time that their agency numbers were creeping up, but he was told to eat healthier exercise more and more activity, but it's not particularly helpful information. But when you know, he got access to a CGM and start using it. He learned so much about how his diet was impacting his glucose and he just started making all kinds of not that dramatic, he didn't like go you know, keto or anything. He just made some some subtle changes that was really impactful to his average glucose, you know, is average glucose was around 150. And he's you know, been working it down to the point where, you know, hopefully he's gonna lower it's able to see you know, below six and a half and get get out of the diet. So,

Scott Benner 10:00
do you see this as a constant wear item? Or do you think it could be educational for them? And then they might not need it after that?

Jake Leach 10:06
I think everyone's gonna be different. I think it's gonna be a lot of different use cases, as we go to this, this broader population. I think, you know, for me, when I think about stello, and the importance of the product, one of the things is really important is to make it extremely engaging, so that people engage with the data. Basically, there's a component of it significant upfront, that's going to be around education, and continuing to understand how different foods do impacts, you know, particular individual. But then there's also the component about reinforcing positive behavior, right? I mean, you can basically when you see your data, you see your average glucose is really in line. It's a constant reminder of boy, you're really doing well, let's keep doing that. I think a lot of people are going to work continuously, we see like when we've used the product in these populations, where we've seen users that are having access to CGM today that are in this group of users that don't take insulin, they do want to keep using it, the were times are very consistent even with what we see in our insulin users. So I do think there's a significant demand out there for this type of product. And the benefits are pretty clear. And CGM is a very cost effective tool for managing the overall cost of somebody that has diabetes. And so we really feel there's an opportunity here to overtime, get get this product reimbursed, but at first it's going to be cash pay at a very affordable competitive price out there in the market.

Scott Benner 11:28
So the pricing will be different than like if I tried to cash by g7

Jake Leach 11:32
Yeah, it's gonna it's gonna be different. It's a different product. It'll be different. We haven't we're not releasing any details exactly around it until we launch but the the goal of this product is to make it accessible to as many people as

Scott Benner 11:45
possible. Launch you're hoping for mid year 2012.

Jake Leach 11:49
Yeah, summertime. Yeah. Summertime. So it's under review by the FDA right now. We submitted it last year. Review is going great. Soon as we get an approval We'll start you know we're we're already working through the stages of getting ready for launch. Yeah, we plan to launch it this summer

Scott Benner 12:00
is that review mostly aimed at the app and the BME because if the device is the same as G seven What's there to review. Far too often we accept the blood glucose meter that someone hands to us, the doctor reaches into a drawer and goes here, take this one. That is that is the one you want. Is that accurate, you have no way of knowing. But if you want accuracy, and you want to be confident in the blood glucose readings that you're getting from your meter, you want that contour next gen. It's incredibly easy to get the same meter that Arden uses, just go to contour next one.com/juicebox That's all you have to do. The contour next gen is easy to use and highly accurate. It features a smart light that provides a simple understanding of your blood glucose levels. And of course, Second Chance sampling technology that can help you to save money with fewer wasted strips, contour next one.com/juicebox I used to hate ordering my daughter's diabetes supplies. I never had a good experience. And it was frustrating. But it hasn't been that way for a while actually for about three years now. Because that's how long we've been using us med us med.com/juicebox or call 888721151 for us med is the number one distributor for FreeStyle Libre systems nationwide. They are the number one specialty distributor for Omni pod dash, the number one fastest growing tandem distributor nationwide, the number one rated distributor index comm customer satisfaction surveys. They have served over 1 million people with diabetes since 1996. And they always provide 90 days worth of supplies and fast and free shipping. US med carries everything from insulin pumps, and diabetes testing supplies to the latest CGM like the libre three and Dexcom G seven. They accept Medicare nationwide and over 800 private insurers find out why us med has an A plus rating with a better business bureau at us med.com/juicebox Or just call them at 888-721-1514. Get started right now. And you'll be getting your supplies the same way we

Jake Leach 14:21
do. You're right it's a it's a simpler review. Because there isn't as much g7 was a massive review for us because we changed so much of the product. It is extending out to 15 days. So we did a clinical study to show I CGM level performance all the way out to 15 days. So there's clinical data review. And then there is a lot of it is the user interface and the human factors. I mean, one of the important things here is for people who get access to this product, understand that they're on insulin, they should have g7 They shouldn't have this product, this product is really for those that don't aren't at risk for hypoglycemia. That's one of the important factors. But yeah, they're basically doing that review. So We're hoping for swift approval and being able to launch this summer. Do you have any concern that if it's so much cheaper in cash, and people can't get covered for g7, that type ones will use it and then not have the safety net of that LOW Alert? is a great question, Scott, something we kind of discussed and organized around eternally saves coverage for g7, when you think about out of pocket costs is really good in the United States if you have coverage, right. So if you have coverage, when it's the lowest out of pocket costs CGM available, on average, you know, a third of our users pay nothing. And then you know, the average copay is less than $40. If someone does get access to it, it is very accurate and reliable from a glucose reading perspective. So I think in that case, you know, you've got a safety safety factor there. But if anyone is using insulin, G seven is really the right, right product for them, because it has those, those safety features. But I think in general, having access to glucose readings is better than nothing. Yeah. So in general, you know, that's one of the reasons why the performance and accuracy is so important, even for this type of product is you really, people need accurate, reliable data. Yeah, it

Scott Benner 16:09
feels like to me the difference between what obviously the FDA has set up as you know, guardrails for keeping people using insulin safe. And that's great for the population. But for one on one people who are stuck, I agree with some things better than nothing. So it's interesting, does this gonna cover for pre diabetes? Do you think

Jake Leach 16:27
that when I think about products, I think about the user groups and designing it for their intended needs, I think there's quite a bit of overlap between people who have pre diabetes and those that have been diagnosed with diabetes, there's a lot of overlap there. But I do feel like our main focus right now is all about this group of type two twos. But you know, we're going to, we're going to continue to evolve. I mean, we're planning a pretty rapid pipeline of enhancements to this product, based on, you know, things that we already have in the hopper in terms of release training that we want to get out features for stello. But also, based on what we learned, once we launched it, right, getting this product out in a large number of people's hands, getting the customer feedback, we've always, you know, we strive to make sure that all the user feedback gets filtered back into the team. And then we develop, we make feature enhancements based on user feedback. That's primarily that's what primarily drives both the features we implement and the timeframes for which we do it. That's going to be exciting kind of release train. And so you know, as overtime, we do feel like there's lots of opportunities to help people, you know, live healthier, lower their average glucose, better mouth, metabolic health,

Scott Benner 17:32
it's all good. I just think that I just had an experience with a family member who wanted to get a GLP. And they're a one C was point one off of being technically having diabetes, saw the doctor literally told her just get your a one C A little higher and come back and I can get it for you.

Jake Leach 17:48
I was like, Well, is this what we're doing know that some of the the way the healthcare systems work and things? Sometimes that is unfortunate that you end up in a situation having to make decisions like that? Yeah, it's crazy.

Scott Benner 18:03
Besides the feedback that comes from the audience all the time about how grateful they are and stuff like that. There was just one person who said, Could you please do more advocating with insurance for other people who would need CGM, they use this as an example, adrenal insufficiency. That's the thing that's not covered. And I guess what they're saying is, if you're ever in a meeting, could you just yell out that too, for other people who experienced low blood sugars but don't fall into these categories?

Jake Leach 18:27
I couldn't. Yeah, I completely agree. I think you know, one of the things when we advocated around Basal coverage with Medicare, we did push very hard for that hypoglycemic people who have hypoglycemia incidents are at risk that aren't on insulin, right? That group is covered under Medicare. And we're working to try and get better coverage by private payers, for anybody who has risk of hypoglycemia, okay? Because we fully understand that it's g7 is a great tool for that group. Getting better insurance coverage is really important.

Scott Benner 19:01
So Jake, as you may imagine, when I reached out to the audience for questions about stello, I also got g7 questions. Of course, is there anything else about stello? Or before I hit you with these, these questions?

Jake Leach 19:14
The only thing I'd say is, you know, people often ask, why do we Why do we name it stello. And so that that word, in Italian, it means stem, and it really stands for growth and resilience, and progress. And that's the way we think about how this, our hopes for it is that it provides that type of support and benefit to people with type two. So it's a it's exciting name, you ended up naming a product that always there's a lot of things that go into that, but it was a really fun journey to land on it.

Scott Benner 19:42
I just assumed you wanted to have commercials that said hello, say hello. And so I didn't think there was much more than that to it, but it's nice to know there's something else to it. That's what I was saying. All right, ready? I'm just gonna start I'm going to start big and then go lower. Usually I would do it the other way, but no reason to tease that out. There's only 10 more minutes in the episode. So Omnipod, five and g7. Yeah, timeframe that you know about anything you're willing to say, hey, net cough twice?

Jake Leach 20:07
Yeah, it's the same, basically is what insolate has said they're tracking? Well, you know, we've done all the validation work. And so we're excited for it to come as quick as possible. So,

Scott Benner 20:18
okay. When people asked me, I tell them, I'm like, that's a Omnipod question. It's not a Dexcom question. But if I don't ask you, I'll get. There'll be pitchforks. So g7 has been out for a little while now. Yeah. Has there been any? Or are there any plan changes or improvements that have happened or happening?

Jake Leach 20:37
Yeah, there's there's quite a bit actually, we've behind the scenes, with any new product, when you launch it, you've got things that were in the pipeline that you wanted to implement, and you launch it, and you continue to implement those enhancements, and also, based on user feedback, and as we see the product performing, we're really happy with how g7 launch has gone globally. And we've made quite a few enhancements, some of the examples would be as we enhance, we put a feature in the Bluetooth called Rapid reconnect. And so what now your g7 does, and we're basically shipping this in all channels. Now, this enhanced Bluetooth, there may be a little bit inventory out there in different channels where they're still with the older version. But this new version is basically it advertises every minute, or reconnection to the phone. So if you ever do lose connection over Bluetooth, it will advertise every five minutes. So it catches back up very quickly, we also enhanced the Bluetooth performance of the radio on the antenna. And so that antenna performance produces a longer range. Really excited about that. So those two kind of went together into the g7. We also have an updated adhesive patch that we're putting in, it's the same patch, it's on stello. And so that is cutting its way into g7, we'll be getting shipping in different channels over time here quickly. And so that that gives it enhanced, where time, in terms of just a little bit stickier, get you out to those that have challenges getting out to 10 and a half days with a patch this this should really help them just call

Scott Benner 22:09
the supplier and yell stickier. Is that how that works.

Jake Leach 22:15
So much that goes into adhesives, particularly around, you know, the durability of them, but also breathability and your potential irritations and irritants and things in there. There's a whole lot that we do before we make a change. And it's a project,

Scott Benner 22:31
is there a world where you'll get to a more sensitivity friendly adhesive that still holds on or does that technology just not exist? No, it

Jake Leach 22:40
does. I mean, we've we've overtime made quite a bit of enhancements, we did it on G six, where we actually had a patch that lasted longer, but also had less irritation than we did with the previous and G seven made another step where irritation was lower with G seven than it was with G six. And the studies we ran, particularly we actually ran studies in people that are you had known sensitivities to medical adhesive, just to better understand how much better g7 was. And so this new patch is even better than that. So it's it's a, you know, the technology continues to evolve. And so I think we're going to continue to see, you know, better technology, better adhesives, we're always, you know, trying to look for the best that's out there and develop it ourselves as well. And we're not stopping and we got to keep making these products, the best we can possibly produce. So

Scott Benner 23:30
I know you guys work hard, and I don't think you just mindlessly forget something.

Jake Leach 23:34
So when I asked you, how come I don't see direct to watch, or Where's delta change and stuff like that? How does that, like how do things get prioritized? I guess? Yeah, it's a great question. We can cover direct to watch too, because that's exciting news. Their main thing is we prioritize it based on user feedback and what we feel, you know, based on the product development team, what we're capable of producing and a certain amount of time, like how we spend our time, and what the prioritization based on user feedback is. And so, Director Watch has been a great example of something that has been highly desirable for a very long time. And we've been working on it at a very strong, dedicated team focused on developing that. And we finally got to the point where we're comfortable with that Apple ecosystem that when you switch to direct to watch mode, your sensor communicating directly to the Apple Watch, without the phone in the communication loop. We're very comfortable that you get all the glucose alerts you need to get because that has now taken over as your number, your main display device where you're getting those critical alerts. That has been what a big part of the journey over multiple years is getting the point where we are confident that that system will always produce those alerts when needed. I work closely with apple on it. They were really helpful in making changes to the Apple Watch operating system to be able to make this happen and We did submit that to the FDA last year. And we do plan to launch it here as soon as it's approved. So that should be coming very soon, based on what you just said, is

Scott Benner 25:07
it possible? I'll see it for stello? Before I see it for g7? Because they don't have the work? You know what I mean? Good. Good. Good

Jake Leach 25:15
question there, Scott. We're not given all the specifics out of bed stello At this point in time, but you'll see it on G seven very soon.

Scott Benner 25:21
If you say good question, I think I'm onto something, hey, this is directly from me and other people too. But nightstand mode now that Apple added that to the phone, like please, that would be amazing. What about delta ready to change and seeing the the last reading for followers like a lot of my stuff here is for for like caregivers, they want to know more about customizable alarms for like school nurses or people who only part time take care of other people with type one, you know, the delta is a big one for them. Basically, what they're saying is that the follow up when you're a caregiver, it shouldn't be different than the user app, because there's a lot of things you have to do and you're blind to those. In that situation, there's a pretty significant portfolio of updates we're going to make to follow. We you know, we've made some over time, but we have been primarily focused on G seven Dexcom, one and stello, getting the user apps updated, but an in built out. But follow is such an important part of our ecosystem for our users. And so I want to I've been pushing the team for more innovation in that area. And we are we have a portfolio of updates we're going to make, it includes a lot of the features that that had been asked for over time. And we'll put them out in order as fast as we can. But it is it is an area where I want us to innovate more. We have a couple of minutes left, and I have a couple of questions that I just know how you're going to answer them already. So I want to ask a bigger question. Is there an inflection point coming with CGM? Or is it just going to continue? Is it like an iPhone? Is it just gonna get a little better every time I get one? Or is there is there a leap to be had? In terms of like, features, performance?

Jake Leach 26:59
All of that? Yeah, I

Scott Benner 27:01
mean, more performance, like stuff, like, you know, listen, I love g7, my daughter, let me be clear, my daughter is at college right now with a 5.6 a one C, like, that's pretty cool. If you asked me to come over there and wash the windows, I'd be happy to do it. So like I'm happy. But first day couple of urgent lows that are fakes, you know, compression lows, you know, that kind of stuff? Like, is there a world where it's just one day? You know what I mean, when they sit around and talk about AI to ever watch a guy sit and talk who really understands it? And he's trying to tell you that 10 years from now, you are not going to understand the world anymore? Like, is there a Is that happening for CGM, in your mind, like in the future? Or is it more of a study as we go?

Jake Leach 27:42
I think so from a performance perspective, just on the accuracy and reliability of the products. There's still plenty of mileage to go. And you mentioned some of the variability on the first day, compression lows, you know, sensor, longevity, all of those things. It's interesting over the evolution of CGM, there's been, you know, big tech problems that we've tackled and solved, right. And those are some of the problems that you mentioned some challenges. That is something that we're very focused on. And you had a lot of very passionate excited team members about continuing to make the most accurate, the best CGM ever right. And so there's going to be more progression there. I think where you're going to see the most though like large step change function type of innovation in CGM is what we start doing with the CGM information, and how we start interacting with both physicians, caregivers and the users. I think that is where the user interface what you're looking at with G seven today is going to be extremely different. You know, as the years go on, and we you know, we're going to continue to launch new platforms, we've got G seven just recently launched, but you know, obviously, GA is well underway. And so those are some of the innovations we're gonna see. It's just, it's, it's really exciting what we can do now that we have, you know, mobile platforms, mobile phones are pretty ubiquitous, and the computing power, and then you got aI starting to come in and you start to think about how one of the things I talked about CES was just the conversational nature of the data presentation to say a physician, helping them get down to the most important thing to discuss with a particular patient could be easily short circuited if you could just rapid fire answer their questions in a conversational format for a particular user based on their real that users data. Yeah, I think it's pretty exciting.

Scott Benner 29:32
Check two things are we talking about? Like I was at this pizza joint last week, you remember last week and when eat the same thing again? Let's go like that kind of stuff. That kind of stuff. Yeah. And I don't think I've ever said this out loud on the podcast, but I've been logging the podcast into an an AI bot, and 1000 hours worth of conversations about diabetes. You would be stunned at how accurately li it answers. So, like granular questions about diabetes, it's really I can't wait like, and I know you guys have been at this for a long time. Like, I know, I have the the honor of kind of seeing the big picture. Like, I remember the first time Kevin said to me, I don't have diabetes, but I were CGM, and I don't eat potatoes anymore. And now look where we are. You know what I mean? Like, like, really like now people with type two diabetes. My brother's a great example. He's already told me, I wear that thing. And I thought, I thought that was good for me. I didn't realize what it was doing to me in the background. And that's, man, that's gotta be eight years ago that he said that to me. You know, so I know people need to be patient. But I remember when you guys started looking at data, and I thought they're gonna do something with that one day. So like, I mean, like, you know, you're not gonna retire soon. Are you Jake? How are you? Good. Okay, all right. Yeah, no,

Jake Leach 30:48
thank you. So this is my 20th year at Dexcom. But I'm not going anywhere. We

Scott Benner 30:51
got a good succession plan that the guy under you knows what he's doing. Yeah. Oh,

Jake Leach 30:55
yeah. Oh, great team. Yeah, absolutely.

Scott Benner 30:57
I don't want the ball getting dropped here. You know, when you decide it's time, you know, I'm sorry. I really appreciate this. I should have you back on more frequently. We haven't done this nearly enough. This we should have. So thank you very much.

Jake Leach 31:09
It was great. Scott really enjoyed your time take care.

Scott Benner 31:20
Huge thanks to us med for sponsoring this episode of The Juicebox Podcast. Don't forget us med.com/juice box. This is where we get our diabetes supplies from you can as well use the link or call 888-721-1514 Use the link or call the number get your free benefits check so that you can start getting your diabetes supplies the way we do from us med. Having an easy to use and accurate blood glucose meter is just one click away. Contour next one.com/juicebox That's right. Today's episode is sponsored by the contour next gen blood glucose meter.

Once there was a time when I just told people if you want a low and stable a one C, just listen to the Juicebox Podcast. But as the years went on, and the podcast episodes grew, it became more and more difficult for people to listen to everyone. So I made the diabetes Pro Tip series. This series is with me and Jenny Smith. Jenny is a Certified diabetes Care and Education Specialist. She's also a registered and licensed dietitian and a type one herself for over 30 years and I of course, am the father of a child who was diagnosed at age two in 2006. The Pro Tip series begins at episode 210 with an episode called newly diagnosed are starting over and from there all about MDI Pre-Bolus Singh insulin pumping, pumping and nudging variables exercise illness, injury surgeries glucagon long term health bumping and nudging how to explain type one to your family. Postpartum honeymoon transitioning all about insulin Temp, Basal. These are all different episodes, setting your Basal insulin, fat and protein pregnancy, the glycemic index and load and so much more like female hormones and weight loss. Head now to juicebox podcast.com. Go up in the menu at the top and click on diabetes pro tip. Or if you're in the private Facebook group, there's a list of these episodes right in the feature tab. Find out how I helped keep my daughter's a one C between five two and six two for the last 10 years without diet restrictions juicebox podcast.com Start listening today. It's absolutely free. You can use the same continuous glucose monitor that Arden uses. All you have to do is go to dexcom.com/juice box and get started today. If you're not already subscribed or following in your favorite audio app, please take the time now to do that. It really helps the show and get those automatic downloads set up so you never miss an episode. Thank you so much for listening. I'll be back very soon with another episode of The Juicebox Podcast. The episode you just heard was professionally edited by wrong way recording. Wrong way recording.com